385 related articles for article (PubMed ID: 18324627)
1. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract][Full Text] [Related]
2. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer.
Tanaka S; Hattori N; Ishikawa N; Shoda H; Takano A; Nishino R; Okada M; Arihiro K; Inai K; Hamada H; Yokoyama A; Kohno N
Int J Cancer; 2012 Jan; 130(2):377-87. PubMed ID: 21351094
[TBL] [Abstract][Full Text] [Related]
3. Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.
Zhao W; Yang Z; Liu X; Tian Q; Lv Y; Liang Y; Li C; Gao X; Chen L
J Int Med Res; 2013 Jun; 41(3):573-83. PubMed ID: 23613495
[TBL] [Abstract][Full Text] [Related]
4. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Fujiwara Y; Kiura K; Toyooka S; Hotta K; Tabata M; Takigawa N; Soh J; Tanimoto Y; Kanehiro A; Kato K; Date H; Tanimoto M
Lung Cancer; 2008 Jan; 59(1):81-7. PubMed ID: 17765355
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Chung FT; Lee KY; Wang CW; Heh CC; Chan YF; Chen HW; Kuo CH; Feng PH; Lin TY; Wang CH; Chou CL; Chen HC; Lin SM; Kuo HP
Int J Cancer; 2012 Aug; 131(3):E227-35. PubMed ID: 22174092
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.
Wang S; Han X; Hu X; Wang X; Zhao L; Tang L; Feng Y; Wu D; Sun Y; Shi Y
Clin Chim Acta; 2014 Mar; 430():63-70. PubMed ID: 24378285
[TBL] [Abstract][Full Text] [Related]
9. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
[TBL] [Abstract][Full Text] [Related]
11. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Pluquet E; Cadranel J; Legendre A; Faller MB; Souquet PJ; Zalcman G; Perol M; Fraboulet G; Oliveiro G; De Fraipont F; Quoix E; Lantuejoul S; Milleron B; Moro-Sibilot D
J Thorac Oncol; 2010 Apr; 5(4):491-6. PubMed ID: 20195171
[TBL] [Abstract][Full Text] [Related]
12. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
[TBL] [Abstract][Full Text] [Related]
13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
Lazzari C; Spreafico A; Bachi A; Roder H; Floriani I; Garavaglia D; Cattaneo A; Grigorieva J; Viganò MG; Sorlini C; Ghio D; Tsypin M; Bulotta A; Bergamaschi L; Gregorc V
J Thorac Oncol; 2012 Jan; 7(1):40-8. PubMed ID: 21964534
[TBL] [Abstract][Full Text] [Related]
16. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Xu CA; Su H; Liu JL; Li L; Zou HW
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
[TBL] [Abstract][Full Text] [Related]
17. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
18. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.
Vollebergh MA; Kappers I; Klomp HM; Buning-Kager JC; Korse CM; Hauptmann M; de Visser KE; van den Heuvel MM; Linn SC
J Thorac Oncol; 2010 Dec; 5(12):1939-48. PubMed ID: 21102259
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
[TBL] [Abstract][Full Text] [Related]
20. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Nishio M; Yamanaka T; Matsumoto K; Kimura H; Sakai K; Sakai A; Sone T; Horiike A; Koizumi F; Kasahara K; Ohira T; Ikeda N; Saijo N; Arao T; Nishio K
J Thorac Oncol; 2011 Nov; 6(11):1889-94. PubMed ID: 21964526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
